Results 1 to 10 of about 25,757 (158)

Myelodysplastic syndromes

HemaSphere, 2019
Johanna Ungerstedt, (Coordinating Author)
doaj   +3 more sources

Myelodysplastic syndromes and autoimmune phenomena – case report and literature overview [PDF]

Liječnički vjesnik, 2023
Myelodysplastic syndromes are a heterogeneous group of hematopoiesis disorders, characterized by dysplastic changes in one or more hematopoietic lineages, ineffective hematopoiesis, and peripheral blood cytopenias.
Ana Zelić Kerep, Ana Kotris, Marino Narančić, Inga Mandac Smoljanović   +3 more
doaj   +1 more source

The myelodysplastic syndromes. [PDF]

BMJ, 1987
The myelodysplastic syndromes constitute a fascinating model for monoclonal premalignant disorders. Haemopoiesis is 'dysplastic' with inefficient maturation of a slowly expanding or sometimes of a stable population, of blood cell precursors. About one third of the patients evolve into acute leukaemia, the result of either a progressive expansion of the
LAYTON, DM, MUFTI, GJ
openaire   +5 more sources

Experiences and Support Needs of Caregivers of Patients with Higher-Risk Myelodysplastic Syndrome via Online Bulletin Board in the USA, Canada and UK

Oncology and Therapy, 2023
Introduction Patients with higher-risk myelodysplastic syndromes (MDS) face considerable challenges in disease management and often require caregiver support.
Pauline Frank, Anne Olshan, Tracey Iraca, Cindy Anthony, Sophie Wintrich, Emma Sasse   +5 more
doaj   +1 more source

Whole exome sequencing reveals a novel LRBA mutation and clonal hematopoiesis in a common variable immunodeficiency patient presented with hemophagocytic lymphohistiocytosis

Experimental Hematology & Oncology, 2021
Common variable immunodeficiency (CVID) was a kind of primary immunodeficiency disorders with heterogeneous phenotype and genotype. Lipopolysaccharide-responsive and beige-like anchor (LRBA) mutation was identified as disease associated in CVID, advanced
Yanling Ren, Feng Xiao, Fei Cheng, Xin Huang, Jianhu Li, Xiaogang Wang, Wei Lang, Xinping Zhou, Jianping Lan, Hongyan Tong   +9 more
doaj   +1 more source

Myelodysplastic Syndromes [PDF]

Acta Haematologica, 2009
The myelodysplastic syndromes (MDS) represent a group of syndromes having in common a defective production of one or more myeloid cell lines. They occur in patients which are more than 50 years old without any sex preponderance. The term MDS is replacing the obsolete and archaic term of’preleukemia’ and/ or ‘oligoblastic leukemia’.
C, Sultan, M, Imbert, H, Jouault, J Y, Scoazec   +3 more
  +7 more sources

Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes

Blood Advances, 2018
: Anemia is the defining feature in most patients with myelodysplastic syndromes (MDS), yet defects in erythropoiesis have not been well characterized. We examined freshly obtained bone marrow (BM) samples for stage-specific abnormalities during terminal
Abdullah Mahmood Ali, Yumin Huang, Ronald Feitosa Pinheiro, Fumin Xue, Jingping Hu, Nicholas Iverson, Daniela Hoehn, Diego Coutinho, Jehanzeb Kayani, Brian Chernak, Joseph Lane, Christopher Hillyer, Naomi Galili, Joseph Jurcic, Narla Mohandas, Xiuli An, Azra Raza   +16 more
doaj   +1 more source

Myelodysplastic syndromes [PDF]

Seminars in Diagnostic Pathology, 2011
Myelodysplastic syndromes (MDS) are hematopoietic neoplasms characterized by an ineffective hematopoiesis associated with cytopenia(s), functional abnormalities of bone marrow lineages, morphologic dysplasia, and a progression to acute myeloid leukemia.
Jiehao, Zhou, Attilio, Orazi, Magdalena B, Czader   +2 more
openaire   +4 more sources

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

Haematologica, 2010
Background Myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders with a high propensity to transform into acute myeloid leukemia.
Felicitas Thol, Eva M. Weissinger, Jürgen Krauter, Katharina Wagner, Frederik Damm, Martin Wichmann, Gudrun Göhring, Christiane Schumann, Gesine Bug, Oliver Ottmann, Wolf-Karsten Hofmann, Brigitte Schlegelberger, Arnold Ganser, Michael Heuser   +13 more
doaj   +1 more source

The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes

Haematologica, 2019
Although cytarabine has been widely considered as one of the chemotherapy drugs for high-risk myelodysplastic syndromes (MDS), the overall response rate is only approximately 20-30%.
Peipei Lin, Yanling Ren, Xiaomei Yan, Yingwan Luo, Hua Zhang, Meenu Kesarwani, Jiachen Bu, Di Zhan, Yile Zhou, Yuting Tang, Shuanghong Zhu, Weilai Xu, Xinping Zhou, Chen Mei, Liya Ma, Li Ye, Chao Hu, Mohammad Azam, Wei Ding, Jie Jin, Gang Huang, Hongyan Tong   +21 more
doaj   +1 more source